Skip to main content

Samjin Pharmaceuticals Co., Ltd. (005500.KS)

KSC Healthcare Drug Manufacturers - Specialty & GenericView data quality →
52.1Fair

ValueMarkers Composite Index

Top 42%#26,067 of 44,707
Undervalued

81% below intrinsic value ($68)

UndervaluedFair ValueOvervalued
Piotroski
5/9
Neutral
Beneish
-2.18
Investigate
Altman
1.73
Distress
DCF Value
$68
Undervalued
ROIC
5.7%
Low
P/E
9.4
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Samjin Pharmaceuticals Co., Ltd. (005500.KS) — VMCI valuation read

Samjin Pharmaceuticals Co., Ltd. sits at VMCI 52/100, with the Healthcare sector median at 50. That 2-point spread is the first thing to note on 005500.KS: it tells the reader the composite is favorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on 005500.KS are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on 005500.KS: 005500.KS trades at 22.0x earnings, 22% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%). The Risk read: net debt to EBITDA of 1.9x is the rate-sensitivity line to watch, anchoring the bear scenario on a measurable balance-sheet metric.

005500.KS rose 4.0% over the trailing 7 days, with a -8.6% read on a 30-day basis.

Samjin Pharmaceuticals Co., Ltd. engages in the research and development of pharmaceutical products in Korea. The company's products include SA001, a clinical Phase II product for the treatment of dry eye and sjogren syndrome; SJP1803/1804, a preclinical stage product for the treatment of macular degeneration; SJP601 and SJP1602 preclinical stage products for the treatment of cancer; SPJ1604 and SPJ003 clinical phase products for the treatment of cancer and diabetes; and SJP1901, SJP1902, SJP1801, and SJP006 biological testing stage products for the treatment of cancer, fibrosis, cancer immunotherapy, alzheimer's disease, Parkinson's disease, and anti-viral disease. The company was founded in 1968 and is headquartered in Seoul, South Korea.

CEO: Kyu Seok Cho586 employeesKRwww.samjinpharm.co.kr

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 005500.KS’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.